Perivascular epithelioid cell neoplasm of the urinary bladder in an adolescent: a case report and review of the literature
© Yin et al.; licensee BioMed Central Ltd. 2012
Received: 2 October 2012
Accepted: 15 December 2012
Published: 31 December 2012
Perivascular epithelioid cell neoplasms (PEComas) of the urinary bladder are extremely rare and the published cases were comprised predominantly of middle-aged patients. Herein, the authors present the first urinary bladder PEComa occurring in an adolescent. This 16-year-old Chinese girl present with a 3-year history of abdominal discomfort and a solid mass was documented in the urinary bladder by ultrasonography. Two years later, at the age of 18, the patient underwent transurethral resection of the bladder tumor. Microscopically, the tumor was composed of spindled cells mixed with epithelioid cells. Immunohistochemically, the tumor were strongly positive for HMB45, smooth muscle actin, muscle-specific actin, and H-caldesmon. Fluorescence in situ hybridization analysis revealed no evidence of EWSR1 gene rearrangement. The patient had been in a good status without evidence of recurrence 13 months after surgery. Urinary bladder PEComa is an extremely rare neoplasm and seems occur predominantly in middle-aged patients. However, this peculiar lesion can develop in pediatric population and therefore it should be rigorously distinguished from their mimickers.
The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1870004378817301
KeywordsPerivascular epithelioid cell neoplasms Urinary bladder Adolescent
Perivascular epithelioid cell neoplasms (PEComas) are defined by the World Health Organization as “mesenchymal tumors composed of histologically and immunohistochemically distinctive perivascular epithelioid cells” . The PEComa family of tumors includes angiomyolipoma (AML), clear cell sugar tumor of the lung (CCST), lymphangioleiomyomatosis (LAM), and rare tumors in other locations . To date, non-AML/non-LAM/non-CCST PEComas have progressively been documented in a variety of anatomical sites, such as visceral organs, soft tissue and bone [3–10]. However, only 12 cases of PEComas of the urinary bladder have been documented in the English-language literature worldwide [11–20]. Herein, we present a urinary bladder lesion occurring in a Chinese adolescent. To the best of our knowledge, the current case is the first published example of bladder PEComa occurring in pediatric population.
The patient’s symptoms were almost relieved completely and she was discharged on the 5th postoperative day. Six months later, a follow-up CT scan and ultrasound were normal. At the most recent follow-up 13 months following the surgery, the patient had been in a good status without evidence of recurrence.
Reported cases of the urinary bladder PEComas in the English-Language Literature and their clinicopathologic features
Nuclear grade and cellularity
MF/ 50 HPF
Pan 2003 
Left lateral inferior /4.0
HMB45 (+), SMA (+), vimentin (−), desmin (−),S-100 protein (−), Melan-A (−), pan-cytokeratin (KL-1) (−), ER (−), PR (−)
Kalyanasundaram 2005 
Left lateral /3.0
HMB45 (+), cytokeratin (−), S-100 (−), synaptophysin (−), vimentin (−), desmin (−), chromogranin A (−)
Parfitt 2006 
Lower abdominal pain and dysuria
Posterior mid-wall /3.0
HMB45 (+), Melan-A (+), SMA (+), desmin (+), c-kit (+), S-100 protein (−), pan-cytokeratin (AE1/AE3) (−), vimentin (−), MSA (−), myoglobin (−), CD31 (−), CD34 (−), WT-1 (−)
Partial cystectomy and partial small bowel resection with adjuvant INF-a immunotherapy
Weinreb 2007 
Dome/urachal remnant cyst /5.0
HMB45 (+), SMA (+), MSA (+), desmin (+), Melan-A (+), S-100 protein (+), MiTF (+), cyclin D1 (+)
Pianezza 2008 
Chronic pelvic pain
Low to moderate
HMB45 (+), S-100 protein (+), H-caldesmon (+), actin (+), Melan-A (−), CD34 (−), A103 (−), pankeratin (−), calretinin (−), CD99 (−), ALK-1 (−), c-kit (−), desmin (−)
Sukov 2009 
Low to moderate
HMB45 (+), SMA (+), tyrosinase (+), desmin (−), Melan-A (−)
Low to moderate
HMB45 (+), pan-cytokeratin (−), vimentin (−), CD56 (−), chromogranin A (−), Melan-A (−), S-100 protein (−), synaptophysin (−), SMA (−), high-molecular-weight cytokeratin (−), inhibin (−)
Yes (related to embolization)
HMB45 (+), SMA (+), vimentin (+), Melan-A (−), tyrosinase (+), S-100 protein (−), c-kit (−), MSA (−), cytokeratin (−)
Embolization and partial cystectomy
Huang 2011 
Frequent micturition and odynuria
Left lateral /9.2
HMB45 (+), vimentin (+), SMA (+), S-100 protein (−), Melan-A (−), synaptophysin (−), c-kit (−), CD34 (−), chromogranin A (−), cytokeratin 8 (−)
Tumorectomy and partial cystectomy
Chan 2011 
Vague urethral pain
Right lateral /6.0
Low to moderate?
HMB45 (+), S-100 protein (+), MiTF (+), SMA (+), calponin (+), vimentin (+), desmin (−), myogenin (−),TFE3 (−), pan-cytokeratin (AE1/AE3) (−), CD34 (−), ALK-1 (−), synaptophysin (−), c-kit (−), Ki67 (+, 1%)
TURBT and then partial cystectomy
Kyrou 2012 
Left posterior /2.7
HMB45(+), S-100 protein (+), EMA (−), cytokeratin (−), desmin(−)
Partial colpectomy and cystectomy/ right ovariectomy/ pelvic lymphadenectomy
Shringarpure 2012 
Left vesicoureteric junction/3
HMB45 (+), Melan-A (+), SMA (+), vimentin (+), MSA (+), S-100 protein (+), cytokeratin (−), desmin(−)
Abdominal discomfort and micturition
HMB45 (+), SMA (+), MSA (+), desmin (−), H-caldesmon (+), Melan-A (−), ALK-1 (−), myogenin (−), EMA (−), pan-cytokeratin (AE1/AE3) (−), S-100 protein (−), Ki-67 (+, 2%)
Microscopically, all of the 13 cases exhibited classic features of PEComa, with admixture of epithelioid and spindled cells arranged radially around blood vessels. Five of 11 cases exhibited infiltrative growth pattern. The mitotic activity of all of the cases was no more than 1/50 HPF. Necrosis was found in 3 of 10 patients, although the necrosis in 1 of the 3 cases might be attributed to prior embolization . Vascular invasion information was limited. Immunohistochemically, most cases exhibited co-expression of melanotic and muscle markers, consistent with immunophenotype of classic PEComa. Notably, HMB45 was the most sensitive marker and all of the 13 cases (100%) showed strong positivity for this reagent. Diffuse immunoreactivity for SMA was observed in 91% (10/11) of cases. In addition, neoplastic cells also showed variable staining for other markers. For instance, Melan-A, desmin, and S-100 protein expression was identified in 30% (3/10), 30% (3/10), 42% (5/12) of lesions, respectively.
The urinary bladder is an extremely rare location for PEComa, especially for pediatric population. The differential diagnosis of this peculiar lesion is broad and sometimes might be very challenging especially in small biopsy samples. This unique lesion must be differentiated from melanotic tumors and other more common types of pediatric bladder mesenchymal lesions, such as smooth muscle tumors, rhabdomyosarcoma, and pseudosarcomatous myofibroblastic proliferation.
This unique lesion can be confused with CCSST and melanoma because of the strong positivity for melanotic markers, especially when neoplastic cells express S-100 protein. However, melanotic tumors can be distinguished from PEComa in several respects. First, cells of melanotic neoplasms are characterized by large and conspicuous nucleoli. Second, strong S-100 protein expression is usually detected in most melanotic tumors but only in a minority of PEComas . Third, the majority of PEComas also express muscle markers, whereas most melanotic tumors are negative for actin. Fourth, and most importantly, identification of t(12;22)(q13;q12)(EWSR1-ATF1) or t(2;22)(q34;q12)(EWSR1/CREB1) fusion can be invaluable in distinguishing CCSST from PEComa .
Smooth muscle tumors can mimic PEComa, as both tumor types express muscle markers. Smooth muscle tumors usually arrange in fascicles, demonstrating ‘cigar-shaped’ nuclei and more eosinophilic cytoplasm. Immunohistochemically, the majority of smooth muscle tumors express strong positivity for desmin, whereas PEComas are usually desmin-negative or express desmin only focally. It is noteworthy to mention that very rare true smooth muscle tumors can express HMB45 ; however, the staining is focally and usually not strong, while most of PEComas usually show diffuse and strong HMB45 expression.
Both rhabdomyosarcoma and pseudosarcomatous myofibroblastic proliferation are more common in this site, especially for very young patients. Additionally, these two lesions express muscle markers. However, detailed morphologic inspection combined with negativity for melanotic markers in these two lesions can be very valuable in distinguishing them from PEComas [27–29].
Lastly, pediatric PEComas of the urinary system sometimes may be confused with renal carcinoma associated with Xp11.2 translocations/TFE3 gene fusions, which usually affect children and young adults [30–32]. Of note, a small minority of this peculiar renal carcinoma may demonstrate immunoreactivity for HMB45 and is usually negative for epithelial markers [30, 32]. However, careful morphologic inspection, in conjunction with the immunostaining pattern and even genetic studies can be useful in this differential diagnosis.
In 2005, a criterion for the classification of PEComas as “benign”, “uncertain malignant potential” and “malignant” was proposed by Folpe et al. . Most PEComas behave in a benign fashion and rare clinically malignant PEComas with distant metastasis have been described [7–10, 33]. Following this classification system suggested by Folpe et al., at least 4 of the cases (cases 2, 3, 4, and 6) could be classified as malignant lesions. However, based on the follow-up information available in 9 of the cases (including 3 of the malignant lesions), there have been no reports of recurrence or metastasis to date, implying that PEComas of urinary bladder might be indolent. However, the following factors need to be considered prior to drawing such a conclusion. First, the number of cases was limited, and the clinical follow-up period (average: 22.8 months; range: 3–72 months) of >12 months was available only in 5 cases (average: 36.8 months; range: 13–72 months). Second, whether the histological grade of urinary bladder PEComas exhibits a linear association with their clinical behavior remains unknown. Generally speaking, the behavior of urinary bladder PEComas seems to be unpredictable, indicating the necessity for the further investigation of more cases with long-term follow-up.
Currently, the optimal treatment for PEComas is not known. Among the 13 cases, 9 patients underwent partial cystectomy and 4 of them received TURBT. Complete excision seems to be curative and might be necessary to avoid progression. Notably, 1 patient was treated by postoperative adjuvant INF-α immunotherapy . However, further investigation is warranted to evaluate the efficacy of adjuvant postoperative therapy in these unusual lesions.
Urinary bladder PEComa is an extremely rare neoplasm and usually occur in middle-aged patients. The present case represents the first one occurring in an adolescent, indicating that this peculiar lesion can affect pediatric population. Therefore, pediatric bladder PEComa should be rigorously distinguished from other more common types of bladder lesions. Bladder PEComas exhibited classic features of PEComa. All of the lesions seem to behave in an indolent fashion although some tumors revealed malignant morphology. Nonetheless,, the behavior of PEComa in this site remains unpredictable. Further studies, including additional large numbers of cases and longer-term follow-up periods are necessary. Additionally, cytogenetic or molecular biological investigation is also warranted to better delineate this peculiar lesion.
Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
This study was supported by National Natural Science Foundation of China (no. 30971148 and no. 81272944).
Perivascular epithelioid cell neoplasm
Clear cell sugar tumor of the lung
Clear cell sarcoma of soft tissue.
- Folpe AL: Neoplasms with perivascular epithelioid cell differentiation (PEComas). World health organization classification of tumours: pathology and genetics of tumours of soft tissue and bone. Edited by: Fletcher CDM, Unni KK, Mertens F. 2002, Lyon: IARC Press, 221-222.Google Scholar
- Folpe AL, Kwiatkowski DJ: Perivascular epithelioid cell neoplasms: pathology and pathogenesis. Hum Pathol. 2010, 41: 1-15. 10.1016/j.humpath.2009.05.011.View ArticlePubMedGoogle Scholar
- Hornick JL, Fletcher CD: PEComa: what do we know so far?. Histopathology. 2006, 48: 75-82. 10.1111/j.1365-2559.2005.02316.x.View ArticlePubMedGoogle Scholar
- Armah HB, Parwani AV: Perivascular epithelioid cell tumor. Arch Pathol Lab Med. 2009, 133: 648-654.PubMedGoogle Scholar
- Martignoni G, Pea M, Reghellin D, Zamboni G, Bonetti F: PEComas: the past, the present and the future. Virchows Arch. 2008, 452: 119-132. 10.1007/s00428-007-0509-1.PubMed CentralView ArticlePubMedGoogle Scholar
- Fang CL, Lin YH, Chen WY: Microscopic endometrial perivascular epithelioid cell nodules: a case report with the earliest presentation of a uterine perivascular epithelioid cell tumor. Diagn Pathol. 2012, 7: 117-10.1186/1746-1596-7-117.PubMed CentralView ArticlePubMedGoogle Scholar
- Harris GC, McCulloch TA, Perks G, Fisher C: Malignant perivascular epithelioid cell tumour (“PEComa”) of soft tissue: a unique case. Am J Surg Pathol. 2004, 28: 1655-1658. 10.1097/00000478-200412000-00017.View ArticlePubMedGoogle Scholar
- Pan CC, Yang AH, Chiang H: Malignant perivascular epithelioid cell tumor involving the prostate. Arch Pathol Lab Med. 2003, 127: E96-E98.PubMedGoogle Scholar
- Bonetti F, Martignoni G, Colato C, Manfrin E, Gambacorta M, Faleri M, Bacchi C, Sin VC, Wong NL, Coady M, Chan JK: Abdominopelvic sarcoma of perivascular epithelioid cells. Report of four cases in young women, one with tuberous sclerosis. Mod Pathol. 2001, 14: 563-568. 10.1038/modpathol.3880351.View ArticlePubMedGoogle Scholar
- Yamashita K, Fletcher CD: PEComa presenting in bone: clinicopathologic analysis of 6 cases and literature review. Am J Surg Pathol. 2010, 34: 1622-1629.PubMedGoogle Scholar
- Pan CC, Yu IT, Yang AH, Chiang H: Clear cell myomelanocytic tumor of the urinary bladder. Am J Surg Pathol. 2003, 27: 689-692. 10.1097/00000478-200305000-00013.View ArticlePubMedGoogle Scholar
- Kalyanasundaram K, Parameswaran A, Mani R: Perivascular epithelioid tumor of urinary bladder and vagina. Ann Diagn Pathol. 2005, 9: 275-278. 10.1016/j.anndiagpath.2005.05.003.View ArticlePubMedGoogle Scholar
- Parfitt JR, Bella AJ, Wehrli BM, Izawa JI: Primary PEComa of the bladder treated with primary excision and adjuvant interferon-alpha immunotherapy: a case report. BMC Urol. 2006, 6: 20-10.1186/1471-2490-6-20.PubMed CentralView ArticlePubMedGoogle Scholar
- Weinreb I, Howarth D, Latta E, Ghazarian D, Chetty R: Perivascular epithelioid cell neoplasms (PEComas): four malignant cases expanding the histopathological spectrum and a description of a unique finding. Virchows Arch. 2007, 450: 463-470. 10.1007/s00428-007-0378-7.View ArticlePubMedGoogle Scholar
- Pianezza ML, Slatnik J, Evans HJ: Clear cell myomelanocytic tumour: minimally invasive treatment of a rare bladder tumour. Can Urol Assoc J. 2008, 2: 230-234.PubMed CentralPubMedGoogle Scholar
- Sukov WR, Cheville JC, Amin MB, Gupta R, Folpe AL: Perivascular epithelioid cell tumor (PEComa) of the urinary bladder: report of 3 cases and review of the literature. Am J Surg Pathol. 2009, 33: 304-308. 10.1097/PAS.0b013e3181854929.View ArticlePubMedGoogle Scholar
- Huang Y, Lu G, Quan J, Sun H, Li H, Hu H, Guo J: Primary perivascular epithelioid cell tumor of the bladder. Ann Diagn Pathol. 2011, 15: 427-430. 10.1016/j.anndiagpath.2010.07.006.View ArticlePubMedGoogle Scholar
- Chan AW, Chan CK, Chiu Y, Yip SK, Lai FM, To KF: Primary perivascular epithelioid cell tumour (PEComa) of the urinary bladder. Pathology. 2011, 43: 746-749. 10.1097/PAT.0b013e32834c768b.View ArticlePubMedGoogle Scholar
- Kyrou D, Staios D, Papatsoris AG: Bladder perivascular epithelioid cell tumor: a novel rare neoplasm. Urol Int. 2012, 88: 480-482. 10.1159/000332199.View ArticlePubMedGoogle Scholar
- Shringarpure SS, Thachil JV, Maya M: PEComa of the urinary bladder. Saudi J Kidney Dis Transpl. 2012, 23: 1032-1034.View ArticlePubMedGoogle Scholar
- Wang GW, Wang Y, Chen YX, Li Q, Shen DH: Perivascular epithelioid cell tumor of urinary system: a clinicopathologic analysis of 21 cases. Zhonghua Bing Li Xue Za Zhi. 2012, 41: 443-447.PubMedGoogle Scholar
- Cai JN, Shi M, Wang J: Perivascular epithelioid cell tumor, not otherwise specified: a clinicopathologic and immunohistochemical analysis of 31 cases. Zhonghua Bing Li Xue Za Zhi. 2011, 40: 240-245.PubMedGoogle Scholar
- Alaggio R, Cecchetto G, Martignoni G, Bisogno G, Cheng L, Sperli D, D’Amore ES, Dall’Igna P: Malignant perivascular epithelioid cell tumor in children: description of a case and review of the literature. J Pediatr Surg. 2012, 47: e31-e40.View ArticlePubMedGoogle Scholar
- Yang W, Li G, Wei-qiang Z: Multifocal PEComa (PEComatosis) of the female genital tract and pelvis: a case report and review of the literature. Diagn Pathol. 2012, 7: 23-10.1186/1746-1596-7-23.PubMed CentralView ArticlePubMedGoogle Scholar
- Wang WL, Mayordomo E, Zhang W, Hernandez VS, Tuvin D, Garcia L, Lev DC, Lazar AJ, Lopez-Terrada D: Detection and characterization of EWSR1/ATF1 and EWSR1/CREB1 chimeric transcripts in clear cell sarcoma (melanoma of soft parts). Mod Pathol. 2009, 22: 1201-1209. 10.1038/modpathol.2009.85.View ArticlePubMedGoogle Scholar
- Silva EG, Deavers MT, Bodurka DC, Malpica A: Uterine epithelioid leiomyosarcomas with clear cells: reactivity with HMB-45 and the concept of PEComa. Am J Surg Pathol. 2004, 28: 244-249. 10.1097/00000478-200402000-00013.View ArticlePubMedGoogle Scholar
- Folpe AL, Mentzel T, Lehr HA, Fisher C, Balzer BL, Weiss SW: Perivascular epithelioid cell neoplasms of soft tissue and gynecologic origin: a clinicopathologic study of 26 cases and review of the literature. Am J Surg Pathol. 2005, 29: 1558-1575. 10.1097/01.pas.0000173232.22117.37.View ArticlePubMedGoogle Scholar
- Folpe AL: Tumors of miscellaneous type or uncertain lineage. Bone and soft tissue pathology foundations in diagnostic pathology. Edited by: Folpe AL, Inwards CY. 2009, Philadelphia: Elsevier, 290-292.Google Scholar
- Weiss SW, Goldblum JR: Soft Tissue Tumors. Soft tissue tumors of intermediate malignancy of uncertain type. 2008, St. Louis: Mosby, 1138-1160. 5Google Scholar
- Argani P, Aulmann S, Karanjawala Z, Fraser RB, Ladanyi M, Rodriguez MM: Melanotic Xp11 translocation renal cancers: a distinctive neoplasm with overlapping features of PEComa, carcinoma, and melanoma. Am J Surg Pathol. 2009, 33: 609-619. 10.1097/PAS.0b013e31818fbdff.View ArticlePubMedGoogle Scholar
- Armah HB, Parwani AV, Surti U, Bastacky SI: Xp11.2 translocation renal cell carcinoma occurring during pregnancy with a novel translocation involving chromosome 19: a case report with review of the literature. Diagn Pathol. 2009, 4: 15-10.1186/1746-1596-4-15.PubMed CentralView ArticlePubMedGoogle Scholar
- Argani P, Lui MY, Couturier J, Bouvier R, Fournet JC, Ladanyi M: A novel CLTC-TFE3 gene fusion in pediatric renal adenocarcinoma with t(X;17)(p11.2;q23). Oncogene. 2003, 22: 5374-5378. 10.1038/sj.onc.1206686.View ArticlePubMedGoogle Scholar
- Armah HB, Parwani AV: Malignant perivascular epithelioid cell tumor (PEComa) of the uterus with late renal and pulmonary metastases: a case report with review of the literature. Diagn Pathol. 2007, 2: 45-10.1186/1746-1596-2-45.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.